Loading
A phase 3 trial of Puxitatug samrotecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by AstraZeneca, now recruiting.
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) is a phase 3 interventional study registered as NCT07044336 by AstraZeneca, with 800 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-10-15. Interventions recorded: Puxitatug Samrotecan, Doxorubicin, Paclitaxel. Conditions listed: Endometrial Cancer, Malignant Solid Tumour. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, AstraZeneca.
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel, AstraZeneca.
Shares Puxitatug samrotecan, Endometrial cancer, AstraZeneca, Antibody-drug conjugate (ADC).
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/